✦ LIBER ✦

Combining bevacizumab and panitumumab with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as second-line treatment in patients with metastatic colorectal cancer

✍ Scribed by Liang, Hong-Liang; Hu, Ai-Ping; Li, Sen-Lin; Liu, Ji-Yong

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

First-line panitumumab plus irinotecan/5

✍ Claus-Henning Köhne; Ralf Hofheinz; Laurent Mineur; Henry Letocha; Richard Greil 📂 Article 📅 2011 🏛 Springer-Verlag 🌐 English ⚖ 584 KB

Safety and efficacy of second-line treat

✍ Xie, Song; Han, Guoping; Fan, Zhikun; He, Lifeng; Xu, Wenbing; Qin, Zhen 📂 Article 📅 2014 🏛 Springer US 🌐 English ⚖ 253 KB

Bevacizumab plus irinotecan, 5-fluoroura

✍ Deng, Ting; Zhang, Le; Liu, Xiao-jian; Xu, Jian-ming; Bai, Yu-xian; Wang, Yan; H 📂 Article 📅 2013 🏛 Springer US 🌐 English ⚖ 199 KB

Panitumumab with Irinotecan/Leucovorin/5

✍ Jordan Berlin; James Posey; Simon Tchekmedyian; Eddie Hu; David Chan; Imtiaz Mal 📂 Article 📅 2007 🏛 CIG Media Group, LP. 🌐 English ⚖ 153 KB

Bevacizumab in combination with biweekly

✍ García-Alfonso, P; Muñoz-Martin, A J; Alvarez-Suarez, S; Jerez-Gilarranz, Y; Rie 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 243 KB

Simvastatin plus irinotecan, 5-fluoroura

✍ Jeeyun Lee; Kyung Hae Jung; Young Suk Park; Joong Bae Ahn; Sang Jun Shin; Seock- 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 284 KB